Teva Pharma Industries Ltd ADR vs Bristol-Myers Squibb: why the prices moved differently

• ▲

  Analysts raise Teva's fair value and initiate with high price targets on CNS transformation Analysts lifted Teva's fair value to $45.30 and initiated coverage with price targets of $50–$55, citing the company's shift toward brain and nerve drugs. This boosts investor confidence and can pull the stock price higher as more analysts recommend buying.

  This is the latest and most direct analyst action that answers why TEVA is moving now.

• ▲

  Teva study shows AUSTEDO preferred by doctors for older tardive dyskinesia patients New data presented at a medical conference shows doctors are most likely to choose Teva's AUSTEDO for older patients with tardive dyskinesia, based on safety and long-term data. This supports continued sales growth for a key Teva drug, which helps earnings and the stock price.

  It provides fresh evidence that Teva's branded drug strategy is gaining traction with prescribers.

• ▲

  Teva bids up to $125 million for BioXcel assets, expanding neuroscience portfolio Teva agreed to be the lead bidder for BioXcel's assets, including the agitation drug IGALMI, for up to $125 million. If approved, this adds a new product to Teva's neuroscience lineup and shows it is investing in growth, which can lift the stock.

  It is a concrete capital move that expands Teva's pipeline and signals confidence in its CNS strategy.

• ▼

  Legal setbacks: Turkey antitrust probe and delayed generic launch for Lupkynis Turkey's competition authority opened an antitrust probe into Teva's patent practices, and Teva agreed to delay its generic version of Aurinia's Lupkynis until 2036. These events create regulatory uncertainty and postpone a potential revenue source, which can weigh on the stock.

  These are new negative regulatory developments that could hurt Teva's reputation and future sales.

Based on 7 stories →

• ▲

  Teva's 'Pivot to Growth' Strategy Accelerates Teva said its growth strategy is accelerating, with debt cut, investment-grade ratings secured ahead of plan, and raised sales targets for key drugs like AUSTEDO and AJOVY. This boosts confidence in future revenue and earnings, supporting a higher stock price.

  This is a major update on Teva's strategic progress, directly impacting investor confidence and future growth prospects.

• ▲

  New Schizophrenia Data Supports Potential Blockbuster New Phase 3 data for TEV-'749, a long-acting schizophrenia treatment, showed high stabilization and low relapse rates. With an FDA decision expected soon, this could become a significant new product, driving future revenue and stock gains.

  This is new clinical data that de-risks a key pipeline asset and highlights near-term regulatory catalyst.

• ▲

  CEO Details Margin Expansion and Cost Savings Teva's CEO outlined a plan to expand gross margin to ~55% and achieve a 30% operating margin by 2027, backed by $700 million in cost savings. The innovative business grew 40% in Q2, showing the strategy is working and boosting profitability outlook.

  This provides concrete financial targets and evidence of margin improvement, key drivers for earnings and stock valuation.

• ▲

  Teva Expands Biosimilar Pipeline with Samsung Bioepis Deal Teva signed a global deal with Samsung Bioepis for up to six biosimilar candidates, adding to its pipeline. This expands Teva's biosimilar portfolio and commercial reach, supporting long-term growth in a high-margin area.

  This is a new partnership that strengthens Teva's biosimilar business, a key growth driver.

Based on 6 stories →

• ▲

  Duvakitug Phase 3 Potential Teva's duvakitug, co-developed with Sanofi, is entering Phase 3 trials for ulcerative colitis and Crohn's disease after strong Phase 2b results. Analysts project peak annual sales of $2–5 billion, which could fuel another 50% stock rally. This pipeline success supports future revenue growth and investor optimism.

  This is a new pipeline catalyst that could significantly boost Teva's long-term revenue and stock price.

• ▲

  Raised 2026 Revenue Guidance Teva raised its 2026 revenue midpoint by $75 million, driven by strong sales of AUSTEDO, AJOVY, and UZEDY. Combined revenue for these three drugs is now expected at about $3.7 billion. This shows Teva's branded drug strategy is working and boosts confidence in future earnings.

  This is a new guidance raise that directly reflects stronger-than-expected demand for Teva's key products.

• ▲

  Direct NYSE Listing and Q2 Sales Beat Teva will replace its ADRs with common stock listed directly on the NYSE starting September 14, which could attract more institutional and retail investors. Q2 sales of $4.1 billion beat estimates, though adjusted EPS missed. The listing change and sales beat drove a 12.3% weekly gain.

  This is a new capital markets event that improves liquidity and investor access, supporting the stock price.

• ▲

  $4.9B Debt Refinancing Teva priced $4.9 billion in new senior notes to refinance higher-cost debt, lowering interest expenses. The new notes carry lower coupons than the debt being redeemed, which will improve cash flow and profitability. This strengthens Teva's balance sheet and supports earnings growth.

  This is a new financing action that reduces interest costs and improves financial flexibility, directly benefiting the stock.

Based on 7 stories →

• ▲

  Teva to acquire BioXcel's IGALMI and BXCL501 assets out of bankruptcy Teva is the stalking horse bidder for BioXcel's assets, including IGALMI and a potential at-home agitation treatment. This adds a commercial drug and a late-stage product to Teva's portfolio, which can boost future revenue. The market initially sent Teva shares down 1%, but the long-term growth potential is positive.

  This is a new acquisition that expands Teva's product portfolio and could drive future revenue.

• ▲

  FDA accepts Alvotech's BLA for subcutaneous Entyvio biosimilar, partnered with Teva Alvotech's application for a subcutaneous version of Entyvio, a treatment for ulcerative colitis and Crohn's disease, has been accepted by the FDA. Teva will commercialize it if approved. This advances Teva's biosimilar pipeline, offering a new revenue stream and strengthening its competitive position in immunology.

  This regulatory milestone for a partnered product expands Teva's biosimilar offerings and future sales potential.

• ◆

  Teva agrees to Medicaid price cuts and MFN pricing in exchange for tariff relief Teva joined nine other drugmakers in deals to lower Medicaid drug prices to match foreign prices, and to supply 45 tons of metronidazole to the government stockpile. In return, Teva gets relief from import tariffs on pharmaceutical ingredients. The price cuts may pressure revenue, but tariff relief and regulatory clarity are positives.

  This is a major new regulatory and pricing agreement that directly affects Teva's revenue and costs.

Based on 6 stories →

• ▲

  Ecopipam NDA submitted for pediatric Tourette syndrome Teva filed for FDA approval of ecopipam, a first-in-class Tourette therapy with strong Phase 3 data. If approved, it would be the first new option in over a decade, adding a new branded revenue stream and boosting long-term growth prospects.

  This is a new pipeline catalyst that could drive future sales and shows Teva's innovative focus.

• ▲

  Austedo data reinforces growth driver status New clinical data shows Austedo improves symptoms in most tardive dyskinesia and Huntington's chorea patients. As Teva's biggest growth driver, strong data supports continued sales growth, which is key to offsetting generic declines.

  This reinforces the growth story for Teva's top branded drug, directly impacting revenue outlook.

• ▲

  European launch of Eylea biosimilar expands market Teva launched Ahzantive, a biosimilar to Eylea, in several European countries. This expands its biosimilar portfolio and adds a new source of revenue in ophthalmology, supporting the company's shift toward higher-margin products.

  New product launch in a major market adds incremental revenue and shows execution of biosimilar strategy.

• ▲

  Global licensing deal for Ocrevus biosimilar Teva signed a deal with Polpharma Biologics to commercialize a proposed Ocrevus biosimilar worldwide. This expands Teva's biosimilar pipeline and supports its Pivot to Growth strategy, with Teva handling regulatory and commercialization.

  This strategic deal adds a high-value biosimilar to Teva's pipeline, enhancing long-term growth potential.

Based on 6 stories →

• ▲

  Reblozyl Sales Near $1.3 Billion, FDA Sets 2027 Decision Reblozyl sales hit nearly $1.3 billion in the first half of 2026, up 23%, as it helps replace older drugs losing patent protection. The FDA accepted a supplemental application for use in myelofibrosis-associated anemia, with a decision expected by March 2027. This supports future revenue growth and lifts BMY's outlook.

  Shows a key growth drug's strong sales and a regulatory step that could expand its use, directly supporting BMY's revenue replacement story.

• ▲

  Zenbexus Launch Advances with Onco360 Pharmacy Network Bristol selected Onco360 for the specialty pharmacy network of its newly approved myeloma drug Zenbexus, moving the launch forward. Getting the drug to patients is key to replacing revenue from older myeloma drugs facing generic competition. Successful rollout could add a new blockbuster stream over time.

  Highlights concrete progress in commercializing a new drug that is central to offsetting patent losses.

• ▲

  Bristol Raises Guidance and Builds $2.3 Billion Houston Campus Bristol raised its full-year revenue guidance to about $49–50 billion and announced a $2.3 billion manufacturing campus in Houston. The guidance raise signals confidence in the business, while the plant expands capacity for future drugs. Both support the stock by improving the profit outlook and long-term supply.

  Guidance raise and major investment show management's confidence and capacity for growth, key drivers for the stock.

• ▼

  Patent Cliff and Weak Financials Weigh on Sentiment Analysts warn that Bristol's low valuation reflects looming patent expirations on Revlimid, Pomalyst, and Eliquis, which will cause revenue declines. One report also flagged weak long-term financials: slow revenue growth, falling margins, and declining earnings per share. These concerns keep a lid on the stock despite new drug progress.

  Presents the main counterweight: patent losses and weak financial trends that could pressure the stock even as new drugs grow.

Based on 12 stories →

• ▲

  Growth Portfolio Now 56% of Revenue, EPS Estimates Raised Bristol's growth products (Opdivo, Camzyos, Sotyktu, etc.) now make up 56% of total revenue, up from 51.8% a year ago, with first-half sales up 13%. Analysts have raised 2026 EPS estimates to $6.91 from $6.34, reflecting confidence that new drugs are replacing older ones losing patent protection. This supports a higher stock price.

  Shows the core shift from legacy to growth products that is driving earnings upgrades and investor optimism.

• ▲

  Zenbexus (iberdomide) Wins FDA Approval and Shows Strong Phase 3 Data The FDA granted accelerated approval to Zenbexus for multiple myeloma, the first in a new drug class. In a Phase 3 trial, it doubled the rate of deep responses (MRD-negative complete responses) versus standard treatment. This adds a potential blockbuster revenue stream and validates Bristol's pipeline, lifting the stock.

  A new approved drug with superior efficacy data is a major growth catalyst that directly boosts future revenue expectations.

• ▲

  Sotyktu Shows Sustained Two-Year Efficacy in Psoriatic Arthritis Bristol's Sotyktu maintained strong efficacy and safety over two years in patients with psoriatic arthritis, with responses improving through week 104. This supports the drug's long-term use and potential to capture more market share in a large patient population, adding to revenue growth.

  Long-term data reinforces the commercial potential of a key growth product, supporting revenue forecasts.

• ▲

  Camzyos Approval Expanded to Pediatric Patients The FDA expanded Camzyos's label to include pediatric patients with obstructive hypertrophic cardiomyopathy, making it the only approved therapy for this age group. This broadens the patient pool and strengthens Camzyos's growth trajectory, a positive for Bristol's revenue outlook.

  Label expansion opens a new patient population, directly increasing the drug's market size and sales potential.

Based on 8 stories →

• ▲

  Zenbexus FDA Approval Adds New Myeloma Growth Driver The FDA approved Bristol's oral Zenbexus for relapsed multiple myeloma, a new revenue stream to help replace older drugs losing patent protection. It's an accelerated approval needing confirmatory trials and faces intense competition, so it builds gradually rather than instantly lifting the stock.

  This is a new drug approval that directly adds a future revenue driver for BMY.

• ▼

  J&J's Oral Psoriasis Pill Approved in China, Threatening Sotyktu Johnson & Johnson won Chinese approval for its once-daily oral psoriasis pill, which will compete with Bristol's Sotyktu in a market of over 8 million patients. This adds competitive pressure that could limit Sotyktu's growth in China, weighing on BMY's sentiment.

  New competitive threat in a key market that could slow BMY's psoriasis drug sales.

• ▲

  Five-Year Camzyos Data Reinforces Long-Term Heart Drug Profile Bristol presented five-year data showing its heart drug Camzyos keeps working safely, with most patients improving. This strengthens confidence in a key growth product and supports its use long-term, a positive for BMY's revenue outlook.

  New clinical data that supports the durability and safety of a key growth drug.

• ▼

  CAR-T Safety Concerns After Novartis Deaths; Bristol Pauses Similar Trials Novartis halted CAR-T trials after three patient deaths, and Bristol paused its own similar trials as a precaution. This raises regulatory and safety worries for Bristol's CAR-T programs, adding uncertainty that can pressure the stock until the reviews clear.

  New safety event that directly affects BMY's CAR-T development and investor risk perception.

• ▲

  Arlo-cel Meets Primary Endpoint in Phase 2 Myeloma Trial Bristol's experimental CAR-T therapy arlo-cel met its main goal in a mid-stage myeloma trial, showing strong response rates in hard-to-treat patients. This is a potential first-in-class treatment that could become a future growth driver, boosting optimism about the pipeline.

  New positive clinical trial result that advances a potential new therapy for BMY.

Based on 6 stories →

• ▲

  Bristol Raises 2026 Revenue Guidance on Eliquis Strength Bristol raised full-year 2026 revenue guidance to $49–$50 billion from $46–$47.5 billion, after Eliquis sales grew 19% to $8.6 billion in the first half. The company now expects Eliquis growth of 20–25% for the year, up from 10–15%, and a smaller decline in older drugs. This directly boosts earnings expectations and investor confidence, pushing BMY shares up.

  This is the most significant new positive catalyst, directly raising revenue and profit outlook.

• ▲

  Bristol Partners with Chai Discovery on AI Antibody Discovery Bristol announced a collaboration with Chai Discovery to use AI and machine learning for discovering new therapeutic antibodies. This aims to speed up drug discovery and strengthen the pipeline, supporting long-term growth. While the impact is not immediate, it reinforces Bristol's commitment to innovation and could lead to new revenue streams, positively influencing investor sentiment.

  This new partnership shows Bristol's ongoing investment in AI to enhance pipeline, a key long-term growth driver.

• ▲

  Bristol to Invest $2.3 Billion in Houston Manufacturing Plant Bristol announced a $2.3 billion investment in a new Houston manufacturing campus, part of a larger $40 billion U.S. investment pledge. The plant will produce small-molecule medicines, biologics, and antibody-drug conjugates, creating jobs and expanding capacity. This move supports long-term supply chain resilience and may ease tariff pressures, positively affecting BMY's outlook.

  This new capital investment demonstrates commitment to U.S. manufacturing and could mitigate tariff risks, a positive for the stock.

• ▼

  Revived $6.7 Billion Celgene Lawsuit Adds Legal Uncertainty A federal appeals court reinstated a $6.7 billion lawsuit alleging Bristol delayed FDA approval of certain drugs to avoid paying contingent value rights to former Celgene shareholders. This brings renewed legal and financial uncertainty, potentially leading to a large cash payout and weighing on investor sentiment. The risk premium on BMY may increase, pressuring the stock price.

  This new legal development introduces a significant potential liability, a negative factor for the stock.

Based on 9 stories →

• ▲

  Q2 earnings beat and raised guidance Bristol reported Q2 revenue of $12.97 billion, beating estimates, and raised full-year guidance. Strong sales of Eliquis and newer drugs like Camzyos and Reblozyl drove the beat. This shows the growth portfolio is replacing lost older-drug sales faster than feared, boosting investor confidence and supporting the stock price.

  This is a major positive event that directly impacts BMY's financial outlook and investor confidence.

• ▼

  AstraZeneca merger talks called off After reports of merger talks, AstraZeneca's board decided to call them off, and Reuters reported no discussions ever took place. The potential takeover premium evaporated, removing a catalyst that had briefly lifted BMY shares. This leaves BMY to face its patent cliff alone, weighing on sentiment.

  The merger speculation was a key driver of BMY's stock movement, and its termination is a significant negative development.

• ▲

  FDA approves ZENBEXUS for multiple myeloma The FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy, for relapsed multiple myeloma. This new treatment offers a potential revenue stream to help offset losses from older drugs facing patent expirations, strengthening BMY's oncology portfolio and long-term growth prospects.

  This is a new product approval that directly addresses BMY's need to replace lost revenue from expiring patents.

• ▲

  Expanded AI partnerships for drug discovery Bristol expanded its partnership with Nvidia to build a next-generation AI supercomputer and struck a deal with Schrödinger to deploy its AI co-scientist Bunsen. These investments aim to speed up drug discovery and reduce costs, supporting long-term pipeline efficiency and innovation.

  These partnerships highlight BMY's commitment to technological innovation, which could improve future drug development and cost efficiency.

Based on 11 stories →

• ▲

  Q2 beat and raised full-year guidance Bristol reported roughly $13.0 billion in quarterly revenue, beating expectations by $1.23 billion, with cancer drugs driving growth. Adjusted earnings per share jumped about 40% to $2.04. Management raised full-year revenue and profit guidance above consensus, signaling the growth portfolio is replacing lost older-drug sales faster than feared.

  This is the core fundamental news of the period and directly supports a higher valuation for BMY.

• ▲

  Reported AstraZeneca merger talks boost BMY shares The Financial Times and other outlets reported preliminary merger discussions between AstraZeneca and Bristol-Myers Squibb that could create a nearly $400 billion drugmaker. BMY shares rose about 8% in premarket trading before fading to near flat, as investors saw a possible takeover premium but also big antitrust hurdles and doubts a deal gets done.

  This is the single biggest new event moving BMY's stock this period and explains the sharp price reaction.

• ◆

  Deal skepticism and antitrust concerns cap the rally AstraZeneca shares fell about 9% while BMY's early 8% gain faded to near flat, showing the market doubts the deal's value and feasibility. Analysts flagged direct competition in lung cancer between Opdivo and Imfinzi, and estimated neither company has the standalone financial firepower to buy the other outright. A deal may never happen.

  It is the essential counterweight to the merger headline and explains why BMY's initial surge did not hold.

Based on 8 stories →

• ▼

  Cytokinetics launches Myqorzo, competing with Camzyos Cytokinetics launched Myqorzo in the U.S. and Germany for the same heart condition Camzyos treats. With over 275 prescribers already, this new rival could steal Camzyos sales, weighing on BMY's revenue growth.

  This is a new competitive threat that directly pressures a key BMY drug.

• ▼

  Trump administration drug-pricing deals include Bristol Myers Squibb Bristol agreed to voluntary most-favored-nation pricing, aligning some U.S. drug prices with lower prices abroad. With top sellers like Revlimid and Eliquis already facing patent expirations, this makes replacing lost revenue even harder.

  This is a new pricing agreement that directly affects BMY's revenue outlook.

• ▲

  FDA accepts mezigdomide application for multiple myeloma The FDA accepted Bristol's application for mezigdomide in relapsed multiple myeloma, with a decision expected by May 2027. The drug showed strong trial results, offering a potential new treatment to help offset lost sales from older drugs.

  This is a new regulatory milestone that advances a promising pipeline drug.

• ▲

  Bristol expands AI drug discovery with NVIDIA and new San Diego hub Bristol is building the most powerful AI supercomputer in life sciences with NVIDIA and opened a 427,000-square-foot San Diego research hub. These investments aim to speed up drug discovery and improve pipeline efficiency, supporting long-term growth.

  These new technology investments could enhance BMY's ability to develop new drugs faster.

Based on 9 stories →

• ▲

  Three pipeline wins in two weeks Bristol reported positive late-stage results for three experimental drugs: SUCCESSOR-2 in multiple myeloma, izalontamab brengitecan in breast and esophageal cancer, and a CAR-T therapy with a 96% response rate. New treatments help replace sales lost as older drugs face cheaper copies.

  This is the main new force lifting BMY: fresh pipeline data that can offset patent losses.

• ▼

  Congress probes China trials A House committee opened an investigation into Bristol over clinical trials at Chinese military hospitals and in Xinjiang. This adds legal and reputational risk, and could lead to restrictions or penalties, which weighs on the stock.

  It is a new regulatory threat that could hurt BMY's reputation and operations.

• ▼

  Medicare price negotiation risk Proposed changes would make Medicare drug price negotiation permanent from 2029 and tighten rules on fixed-combination drugs. This could pressure future U.S. prices for some Bristol medicines, though legal challenges and a broad product mix may soften the blow.

  It flags a new pricing risk that could lower BMY's future revenue.

• ▼

  Roche rival beats Krazati Roche's divarasib outperformed Bristol's Krazati in a Phase III lung cancer trial, meeting survival goals. This competitive threat could erode Krazati's market share and future sales, a negative for BMY.

  It shows a new competitive loss that could reduce BMY's oncology revenue.

Based on 7 stories →